Vimarsana
Biggest News Aggregation in the World

Relative Reduction News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Relative Reduction. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Relative Reduction Today - Breaking & Trending Today

Akero Therapeutics' Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease - Vimarsana News

Akero Therapeutics' Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease

Patients treated with EFX for 12 weeks combined with GLP-1 achieved a 65% relative reduction in liver fat, compared to a 10% relative reduction for GLP-1 alone 88% of patients treated with EFX... | June 5, 2023

Travere Therapeutics Announces Positive Topline Results - Vimarsana News

Travere Therapeutics Announces Positive Topline Results

Data from the four patients treated with the highest dose of pegtibatinase showed a clinically meaningful 67.1% mean relative reduction in total...

Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) - Vimarsana News

Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)

Study Achieves Primary Endpoint, Demonstrating Statistically Significant Reductions in Liver Fat from Baseline to Week 12 in Patients Receiving VK2809 as...

Finerenone Signals Pneumonia, COVID-19 Benefits - Vimarsana News

Finerenone Signals Pneumonia, COVID-19 Benefits

Secondary analyses from 13,026 people with type 2 diabetes and CKD in the finerenone pivotal trials showed that the agent was linked with less infective pneumonia and blunted COVID-19 severity.